Ftse Mib
34.127,62
-0,72%
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
NASDAQ
19.621,68
1,77%
Bitcoin
98.351,90
0,15%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Silo Pharma Inc (SILO) Silo Pharma Inc (SILO) Notizie

Silo Pharma Inc

SILO
0,9899
0,0399 (4,20%)
04 Gen 2025 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
02/1/202517:11EDGAR2Form 8-K - Current report
02/1/202514:45GLOBESilo Pharma Issues Letter to Shareholders Detailing..
20/12/202423:00EDGAR2Form 8-K - Current report
18/12/202413:35GLOBESilo Pharma Initiates Pharmacokinetic and Tolerability Study..
16/12/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/11/202414:05GLOBESilo Pharma Enters Joint Development Agreement for SP-26..
22/11/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/11/202414:40GLOBESilo Pharma Announces Positive Results for Novel SPC-15..
15/11/202423:21EDGAR2Form DEFR14A - Revised definitive proxy soliciting materials
12/11/202422:42EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202422:04EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/11/202422:03EDGAR2Form 8-K - Current report
31/10/202413:35GLOBESilo Pharma Reports Positive Results in Sterilization and..
18/9/202422:19EDGAR2Form ARS - Annual Report to Security Holders
18/9/202422:17EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
18/9/202422:15EDGAR2Form DEF 14A - Other definitive proxy statements
10/9/202412:46EDGAR2Form 8-K - Current report
10/9/202412:35GLOBESilo Pharma Announces Completion of FDA Pre-IND Meeting to..
21/8/202423:20EDGAR2Form S-1 - General form for registration of securities under..
14/8/202420:30GLOBESilo Pharma Expands Development Agreement with Sever Pharma..
13/8/202422:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202414:13GLOBESilo Pharma Announces Partnership with Global CRO for..
26/7/202422:17EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
26/7/202414:20GLOBESilo Pharma to Present at H.C. Wainwright Annual Global..
25/7/202422:30EDGAR2Form S-1/A - General form for registration of securities..
22/7/202423:00EDGAR2Form 8-K - Current report
22/7/202422:45GLOBESilo Pharma Announces Closing of $2.1 Million Registered..
22/7/202412:06EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/7/202414:01GLOBESilo Pharma Announces $2.1 Million Registered Direct..
18/7/202414:25GLOBESilo Pharma and Resyca BV Partner on Device and CMC..
17/7/202422:45EDGAR2Form S-1 - General form for registration of securities under..
16/7/202412:30GLOBESilo Pharma Secures Exclusive Global License for Alzheimer's..
08/7/202422:15EDGAR2Form 8-K - Current report
08/7/202414:45GLOBESilo Pharma Announces Exclusive, Global License for Lead..
26/6/202414:50GLOBESilo Pharma Partners with AmplifyBio to Advance SPC-15 for..
13/6/202423:08EDGAR2Form SC 13G - Statement of acquisition of beneficial..
13/6/202419:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202414:18GLOBESilo Pharma Announces Successful Production of its SP-26..
06/6/202422:52EDGAR2Form 8-K - Current report
06/6/202422:50GLOBESilo Pharma Announces Closing of $2 Million Registered..
06/6/202412:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/6/202414:00GLOBESilo Pharma Announces $2 Million Registered Direct Offering..
04/6/202422:05EDGAR2Form 8-K - Current report
04/6/202414:41GLOBESilo Pharma Submits Pre-Investigational New Drug Application..
21/5/202414:45GLOBESilo Pharma Announces Positive Results from Study for..
14/5/202414:45GLOBESilo Pharma to Participate in FDA Meeting Exploring Emerging..
13/5/202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
23/4/202414:15GLOBESilo Pharma Announces Positive Results for Intranasal PTSD..
10/4/202414:11GLOBESilo Pharma set to Acquire Exclusive Licensing for Promising..
20/3/202413:30GLOBESilo Pharma Exercises Option for Exclusive License Agreement..
Apertura: 0,9497 Min: 0,91 Max: 0,9947
Chiusura: 0,95

La tua Cronologia

NASDAQ
SILO
Silo Pharma
BIT
P1BEJ2
BNP Paribas Issuance
BIT
NSCIT0050830
Sara Assicurazioni
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network